Alpha Teknova (TKNO) AI Stock Analysis

• Market Cap: $257.05M
• Dividend Yield: N/A
• Average Volume (3M): 292.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: 3.79%
• EPS Growth: 55.19%
• Country: US
• Employees: 173
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.09
• Shares Outstanding: 53,440,810
• 10 Day Avg. Volume: 220,976
• 30 Day Avg. Volume: 292,140
• PEG Ratio: -0.57
• Price to Book (P/B): 3.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -33.91
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 1.72
• Enterprise Value/Gross Profit: 31.50
• Enterprise Value/Ebitda: -2.88
• 1Y Price Target: $11.00
• Price Target Upside: 128.69% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 45 Neutral
• Price Target: $5.00 ▲(3.95%Upside)

The overall stock score is largely influenced by financial performance challenges, which overshadow positive aspects from earnings calls and corporate events. The negative valuation metrics and technical indicators further contribute to a low score.

Positive Factors

Financial Performance

Teknova's first-quarter results beat on the top line and were in line on total revenue.

Growth Strategy

Customers shifting orders from stock to custom reagents as programs enter preclinical development should be a tailwind to top-line growth and gross margins.

Liquidity

Management continues to anticipate that cash on hand is likely to provide sufficient liquidity.

Negative Factors

Market Uncertainty

Management noted that some customers have delayed orders and reduced budgets due to macro uncertainty.

Revenue Guidance

2025 revenue guidance of $39-42M is below consensus estimates, leading to modest expected top line growth.

Valuation

The company's premium valuation relative to its small cap peer group is a factor in maintaining a Neutral rating on TKNO.

Alpha Teknova Business Overview & Revenue Model

Company Description

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.

How the Company Makes Money

Alpha Teknova generates revenue through the sale of its proprietary reagents and laboratory solutions to biotechnology and pharmaceutical companies, academic institutions, and research organizations. The company leverages its expertise in bioprocessing and formulation to provide customized solutions that meet the specific needs of its clients. Key revenue streams include direct sales of standard product offerings, as well as custom manufacturing services for tailored reagent solutions. Strategic partnerships and collaborations with leading biotech firms also play a significant role in expanding Teknova's market reach and enhancing its revenue potential.

Alpha Teknova Financial Statement Overview

Summary

Alpha Teknova faces significant financial challenges with declining revenue growth, negative profitability margins, increased leverage, and negative free cash flow trends. The company is not generating sufficient cash from operations and relies heavily on external financing.

Income Statement

The income statement shows a concerning trend with declining revenue growth and negative profitability margins. The gross profit margin has decreased significantly over the years, and the net profit margin remains deeply negative, indicating substantial losses. Despite a slight increase in revenue in the TTM, the company's EBIT and EBITDA margins are substantially negative, reflecting operational inefficiency and high operating costs.

Balance Sheet

The balance sheet shows a decline in stockholders’ equity and a challenging debt position. The debt-to-equity ratio has increased, indicating higher leverage, which poses a financial risk. The equity ratio has deteriorated, showing a decrease in the proportion of equity financing. These factors signal potential financial stability issues, although the company maintains some liquidity.

Cash Flow

The cash flow statement reveals negative free cash flow trends, indicating that the company is not generating sufficient cash from operations to cover capital expenditures. The operating cash flow to net income ratio is negative, highlighting cash flow management challenges. The company is reliant on external financing, as evidenced by positive financing cash flows despite negative operating cash flows.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	37.74M	36.68M	41.42M	36.89M	31.30M
Gross Profit	7.23M	10.30M	17.48M	17.62M	17.75M
EBITDA	-19.57M	-25.54M	-25.69M	-9.13M	6.71M
Net Income	-26.75M	-36.78M	-47.47M	-9.80M	3.57M
Balance Sheet
Total Assets	118.77M	128.59M	152.26M	166.51M	62.91M
Cash, Cash Equivalents and Short-Term Investments	30.40M	28.48M	42.24M	87.52M	5.13M
Total Debt	30.17M	30.46M	42.31M	11.87M	0.00
Total Liabilities	36.38M	38.55M	52.38M	23.31M	46.14M
Stockholders Equity	82.39M	90.04M	99.89M	143.20M	16.77M
Cash Flow
Free Cash Flow	-13.52M	-26.75M	-55.55M	-28.95M	-2.96M
Operating Cash Flow	-12.42M	-18.81M	-27.40M	-9.07M	2.50M
Investing Cash Flow	-27.27M	-7.74M	-28.15M	-17.52M	-1.74M
Financing Cash Flow	14.89M	12.80M	10.27M	110.79M	-1.60M

Alpha Teknova Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.81
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TKNO, the sentiment is Negative. The current price of 4.81 is below the 20-day moving average (MA) of 5.24, below the 50-day MA of 5.83, and below the 200-day MA of 6.61, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 35.41 is Neutral, neither overbought nor oversold. The STOCH value of 62.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TKNO.

Alpha Teknova Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	80 Outperform	$483.66M	10.10	25.47%	10.13%	-23.37%	-39.03%
Sector *	70 Outperform	€3.51B	23.95	22.76%	2.41%	32.58%	18.20%
RMTI	61 Neutral	$38.62M	―	-2.12%	―	12.82%	96.46%
EBS	56 Neutral	$399.48M	―	-21.63%	―	-18.56%	76.88%
LFCR	51 Neutral	$307.31M	―	-83.58%	―	6.88%	-17.54%
AQST	51 Neutral	$398.31M	―	77.48%	―	5.29%	-37.31%
TKNO	45 Neutral	$257.05M	―	-28.76%	―	3.79%	55.19%

Alpha Teknova Corporate Events

Alpha Teknova Approves Key Proposals at Annual Meeting

On June 17, 2025, Alpha Teknova, Inc. held its 2025 Annual Meeting of Stockholders where 88.62% of the company’s common stock was represented. During the meeting, stockholders voted on two key proposals: the election of Class I directors to serve until 2028 and the ratification of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Both proposals were approved, indicating strong support for the company’s leadership and financial oversight.

The most recent analyst rating on (TKNO) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Alpha Teknova stock, see the TKNO Stock Forecast page.